Wednesday, January 21, 2026 The PAC3 (NCT04340141) trial: Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer has closed to accrual after reaching its protocol-specified accrual goal. This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).To find out more information please visit the CCTG PAC3 members trial page.
